MA40457A - Combinaison de médicaments pour traiter le myélome multiple - Google Patents

Combinaison de médicaments pour traiter le myélome multiple

Info

Publication number
MA40457A
MA40457A MA040457A MA40457A MA40457A MA 40457 A MA40457 A MA 40457A MA 040457 A MA040457 A MA 040457A MA 40457 A MA40457 A MA 40457A MA 40457 A MA40457 A MA 40457A
Authority
MA
Morocco
Prior art keywords
multiple myeloma
drug combinations
treat multiple
treat
inhibitor
Prior art date
Application number
MA040457A
Other languages
English (en)
French (fr)
Inventor
Dana T Aftab
Peter Lamb
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA40457A publication Critical patent/MA40457A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA040457A 2014-08-05 2015-08-05 Combinaison de médicaments pour traiter le myélome multiple MA40457A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462033386P 2014-08-05 2014-08-05

Publications (1)

Publication Number Publication Date
MA40457A true MA40457A (fr) 2017-06-14

Family

ID=53836256

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040457A MA40457A (fr) 2014-08-05 2015-08-05 Combinaison de médicaments pour traiter le myélome multiple

Country Status (13)

Country Link
US (1) US11065240B2 (OSRAM)
EP (1) EP3177311B1 (OSRAM)
JP (2) JP6892381B2 (OSRAM)
KR (1) KR102634247B1 (OSRAM)
CN (1) CN106573042A (OSRAM)
AU (1) AU2015301097B2 (OSRAM)
BR (1) BR112017002318A2 (OSRAM)
CA (1) CA2957466C (OSRAM)
EA (1) EA034992B1 (OSRAM)
MA (1) MA40457A (OSRAM)
MX (1) MX382904B (OSRAM)
UA (1) UA121482C2 (OSRAM)
WO (1) WO2016022697A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
RU2748549C2 (ru) 2016-04-15 2021-05-26 Экселиксис, Инк. Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
EP3694878A1 (en) * 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
CN117624045A (zh) 2018-01-26 2024-03-01 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
WO2023222946A1 (en) 2022-05-18 2023-11-23 Fermion Oy Process for the preparation of cabozantinib
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6402215B1 (en) * 1996-05-21 2002-06-11 American Moto Products, Inc. Vehicle cargo bed extender
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
AU2006231646A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-Met modulators and methods of use
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
UY32142A (es) 2008-09-26 2010-05-31 Smithkline Beckman Corp Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
JP5486606B2 (ja) 2008-11-13 2014-05-07 エクセリクシス， インク． キノリン誘導体の調製方法
JP2012511017A (ja) 2008-12-04 2012-05-17 エグゼリクシス， インコーポレイテッド キノリン誘導体の調製方法
KR101733773B1 (ko) 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
AU2010274012A1 (en) 2009-07-17 2012-02-09 Exelixis, Inc. Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy] -quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2011269788B2 (en) * 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
SG184040A1 (en) 2010-03-12 2012-10-30 Exelixis Inc Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
SG10201609324UA (en) 2010-07-16 2017-01-27 Exelixis Inc C-met modulator pharmaceutical compositions
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
CA2812750C (en) 2010-09-27 2020-10-06 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
AU2011307306A1 (en) 2010-09-27 2013-05-02 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012064967A2 (en) * 2010-11-10 2012-05-18 Cedars-Sinai Medical Center Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
JP2013543011A (ja) 2010-11-22 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 癌の治療法
GEP20247677B (en) 2011-02-10 2024-10-10 Exelixis Inc Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
AU2012312364B2 (en) 2011-09-22 2017-11-09 Exelixis, Inc. Method for treating osteoporosis
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
BR112014011009A2 (pt) 2011-11-08 2017-06-06 Exelixis Inc inibidor duplo de met e vegf para tratar câncer
US20150079089A1 (en) * 2012-02-06 2015-03-19 The Regents Of The University Of California Emp2 regulates angiogenesis in cancer cells through induction of vegf
CN103304552B (zh) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
CN104703600A (zh) 2012-09-07 2015-06-10 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
KR102276348B1 (ko) 2013-03-15 2021-07-12 엑셀리시스, 인코포레이티드 Ｎ­（４­〔［６,７­비스（메틸옥시）퀴놀린­４­일］옥시〕페닐）­ｎ′­（４­플루오로페닐）시클로프로판­１,１­디카복사미드의 대사물
BR112015025408A8 (pt) 2013-04-04 2018-07-10 Exelixis Inc combinações de drogas para tratar câncer
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
EP3134084B1 (en) 2014-04-25 2021-03-17 Exelixis, Inc. Method of treating lung adenocarcinoma
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
TW201625243A (zh) 2014-10-14 2016-07-16 艾克塞里克斯公司 用於治療黑素瘤之藥物組合

Also Published As

Publication number Publication date
CA2957466C (en) 2023-10-17
UA121482C2 (uk) 2020-06-10
EP3177311A1 (en) 2017-06-14
CN106573042A (zh) 2017-04-19
KR20170031786A (ko) 2017-03-21
CA2957466A1 (en) 2016-02-11
WO2016022697A1 (en) 2016-02-11
MX382904B (es) 2025-03-13
MX2017001490A (es) 2017-05-11
JP6892381B2 (ja) 2021-06-23
AU2015301097B2 (en) 2021-03-04
US20170224672A1 (en) 2017-08-10
AU2015301097A1 (en) 2017-03-02
KR102634247B1 (ko) 2024-02-05
JP2017526662A (ja) 2017-09-14
EA034992B1 (ru) 2020-04-15
JP2020002179A (ja) 2020-01-09
BR112017002318A2 (pt) 2018-07-17
EP3177311B1 (en) 2024-10-30
EP3177311C0 (en) 2024-10-30
EA201790312A1 (ru) 2017-06-30
US11065240B2 (en) 2021-07-20

Similar Documents

Publication Publication Date Title
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
IL268469B (en) 2-Heteroaryl-3-oxo-3,2-dihydropyridazine-4-carboxamides for cancer treatment
MY184870A (en) Immunomodulators
PH12016501763A1 (en) Multispecific antibodies
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2017000363A (es) Inhibicion de la via de notch.
ECSP17015977A (es) Terapia de combinacion
SI3122358T1 (sl) Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
IN2015DE00625A (OSRAM)
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX379622B (es) Compuestos espirociclicos
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2020007742A (es) Procesos para preparar fluorocetolidos.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
HK1239538A1 (en) Drug combinations to treat multiple myeloma
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
IN2014MU03184A (OSRAM)
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния
UA104671U (uk) Застосування яктону як нейропротектора
TN2014000468A1 (fr) اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها
AU366435S (en) Dry pipe
TN2014000355A1 (fr) طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية